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ABSTRACT
Objective: To summarise how costs and health
benefits will change with the adoption of total
laparoscopic hysterectomy compared to total
abdominal hysterectomy for the treatment of early
stage endometrial cancer.
Design: Cost-effectiveness modelling using the
information from a randomised controlled trial.
Participants: Two hypothetical modelled cohorts of
1000 individuals undergoing total laparoscopic
hysterectomy and total abdominal hysterectomy.
Outcome measures: Surgery costs; hospital bed
days used; total healthcare costs; quality-adjusted life
years; and net monetary benefits.
Results: For 1000 individuals receiving total
laparoscopic hysterectomy surgery, the costs were
$509 575 higher, 3548 hospital fewer bed days were
used and total health services costs were reduced by
$3 746 221. There were 39.13 more quality-adjusted
life years for a 5 year period following surgery.
Conclusions: The adoption of total laparoscopic
hysterectomy is almost certainly a good decision for
health services policy makers. There is 100%
probability that it will be cost saving to health services,
a 86.8% probability that it will increase health benefits
and a 99.5% chance that it returns net monetary
benefits greater than zero.
INTRODUCTION
Endometrial cancer is the most common
gynaecological cancer accounting for
300 000 new diagnoses worldwide.1 In devel-
oped countries, lifetime risk is between 2.5%
and 3% and incidence is rising.2 3 Risk
factors include increasing age, obesity, dia-
betes mellitus, nulliparity, late menopause,
unopposed oestrogen intake or oestrogen
producing tumours, a history of breast
cancer and use of tamoxifen.4 5 Standard
treatment is surgery to remove the uterus,
fallopian tubes and ovaries. In selected
patients, retroperitoneal pelvic and/or aortic
lymph nodes are removed to establish the
extent of the cancer and assist in ongoing
treatment choices. Total laparoscopic hyster-
ectomy (TLH) has been proposed as an
alternative to total abdominal hysterectomy
(TAH) widely used by gynaecological cancer
surgeons and has been tested in three rando-
mised trials worldwide. Patients who had
TLH instead of TAH for uterine cancer had
better postsurgical quality of life (QoL),
fewer complications and shorter hospital
stay.6–8 One study did show an incidence of
major and minor surgical complications as
similar in patients undergoing a TLH or
TAH.9 The aim of the research reported
ARTICLE SUMMARY
Article focus
▪ To evaluate how costs and health benefits
change with the adoption of laproscopic surgery
rather than using laparotomy to treat endometrial
cancer.
Key messages
▪ Surgery costs are higher for laproscopic surgery.
▪ Length of stay in hospital and overall health
services costs are lower for laproscopic surgery.
▪ Health benefits measured by quality-adjusted life
years are higher for laproscopic surgery.
Strengths and limitations of this study
▪ Lower cost and better health outcomes are a
‘win win’ for health services.
▪ The conclusions are easy to interpret for health
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▪ Mortality data were used from a study carried
out in a different jurisdiction.
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here is to identify how costs and health beneﬁts will
change with the adoption of TLH over TAH through
laparotomy for the treatment of early stage endometrial
cancer. A health services perspective is adopted and
quality-adjusted life years (QALYs) estimated.
Information for this modelling study was available from
the LACE trial.10
METHOD
Randomised controlled trial
The LACE trial is registered with clinicaltrials.gov
(NCT00096408) and the Australian New Zealand
Clinical Trials Registry (CTRN12606000261516) and was
approved by all relevant hospital and university human
research ethics committees. A detailed description of
the study including details of the two surgical
approaches has been published previously.6 10 Between
October 2005 and June 2010, 760 patients were
recruited through 1 of the 20 participating tertiary
gynaecological oncology centres in Australia, New
Zealand, Hong Kong and Scotland. Women were eligible
if they were aged 18 years or older, with histologically
conﬁrmed endometrioid adenocarcinoma of the endo-
metrium of any FIGO grade, and had an Eastern
Cooperative Oncology Group (ECOG) score of less than
2. Further inclusion criteria included imaging studies
suggesting the absence of extra-uterine disease. Patients
were excluded from the study if any of the following
criteria were met: histological cell-type other than endo-
metrioid on curettage, clinically advanced disease (stage
II–IV) or bulky lymph nodes on imaging, uterine size
greater than 10 weeks of gestation, estimated life expect-
ancy of less than 6 months, medically unﬁt for surgery,
patient compliance or geographic proximity preventing
adequate follow-up or unﬁt to complete QoL question-
naires. The FIGO criteria for stage (2009) were used.
Randomisation using stratiﬁed permuted blocks was
carried out centrally and independent from other study
procedures through a web-based system at the University
of Queensland. Randomisation was stratiﬁed according
to treating centre and by grade of differentiation as
taken from the endometrial biopsy/D&C.6 10 All sur-
geons on the trial had to be accredited by the trial man-
agement committee before being eligible to enrol
patients. After informed consent was obtained, trial staff
checked eligibility and received notiﬁcation of the allo-
cated treatment via the web-based case report system.
Blinding was not possible due to ethical considerations
and the nature of the treatment.
Primary outcomes from the LACE trial have been pub-
lished6 11 and show the TLH and TAH groups were
similar according to clinical and demographic factors
and the incidence of intra-operative adverse events were
comparable. The incidence of postoperative adverse
events and serious adverse events was signiﬁcantly
higher in the TAH group compared to the TLH group.
There were differences in the rates of lymph node
dissection with 60.2% in the TAH group and 39.9% in
the TLH group and this may inﬂuence adverse events
and costs and the QoL outcomes. The average operating
time was higher for TLH (132 min) as compared to
TAH (107 min), but the median length of stay was lower
for TLH (2 days) as compared to TAH (5 days). QoL
outcomes were published for a subset of the participants
and it show that in the early phase of recovery the TLH
group had better QoL from baseline compared to the
TAH group in all subscales of the Functional Assessment
of Cancer Therapy-General (FACT-G) V.4, except for
emotional and social wellbeing. Some QoL advantages
were still present up to 6 months after surgery.
Cost-effectiveness analysis
A two-state Markov model was used to predict how a gen-
eralised population of patients transitioned into a state
of DEAD from ALIVE for a modelled cohort of 1000
TAH and TLH patients during the 1825 days or 5 years
postsurgery. Daily risks of death were estimated for
either arm of the trial and applied to the two cohorts
based on survival data reported by Walker et al.12 This
was a separate study of mortality risk from laparoscopy
versus laparotomy for comprehensive surgical staging of
uterine cancer and it revealed 5-year survival of 89.8%
for patients randomly assigned to laparoscopy and
89.8% for patients randomly assigned to laparotomy. For
each day of the model, a utility score was assigned to
those in the ALIVE state based on the individual EQ-5D
tariffs reported from trial participants. Values were col-
lected presurgery and 1 week, 4 weeks, 3 months and
6 months postsurgery. The 6-month value was used for
all days from 6 to 12 months. After 12 months, it was
assumed that the QoL was similar for both groups and a
mean score was used until day 1825. Health beneﬁts
arising in future time periods were discounted at 3% in
line with recent guidelines. The costs of the two surgical
treatments included theatre nursing costs, allocated by
duration of procedure; all equipment and consumables
used; and Medicare Beneﬁts Schedule13 items for surgi-
cal and anaesthetics fees for abdominal and laparo-
scopic procedures. The costs of health services used in
the 6 months following surgery were consultations with
doctors other than gynaecology oncology; psychiatrist,
psychologist or other mental health counsellors; nurse
practitioner; home health nurse and physical/occupa-
tional or respiratory therapist; and consultations as an
outpatient and visits to the emergency department. The
number of days in hospital recovering from the initial
surgical treatment and any subsequent admissions
during the 6 months after treatment were aggregated
and valued by a national hospital pricing model14; these
prices were adjusted to 2011 values based on 3% annual
price inﬂation. All costs were valued in Australian dollars
at 2011 prices, health beneﬁts represented by QALYs
and the marginal QALY was given a monetary value of
$64 000.15 Net monetary beneﬁts were estimated by
multiplying each QALY gained by $64 000 and then
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deducting the change to costs. Uncertainty among the
model parameters was included by ﬁtting the individual
data to probability distributions. The β-distribution was
used for transition probabilities and utility scores, and
the γ-distribution was used for the costs.16 One thousand
random samples were taken from the prior distributions
to reveal the joint distribution of cost and QALY out-
comes for patients in both arms of the trial.
Because of different rates of lymph node dissection
among the two groups, an alternate version of the
model that excluded all patients with lymph node dissec-
tion was also evaluated. This scenario analysis will assess
the sensitivity of the conclusions to any bias on out-
comes arising from the differences in rates of lymph
node dissection.
RESULTS
The mean and SD for the EQ-5D scores for TAH and
TLH for 1 week, 4 weeks, 3 months and 6 months post-
surgery are shown in table 1. The difference in QoL out-
comes is modest, but is the largest in 1 week postsurgery
and then reduces over time.
The costs of theatre time, equipment and consumables
were provided by the Royal Brisbane and Women’s
Hospital and were $1734.49 for a TLH case and $957.42
for a TAH case. Medicare Beneﬁts Schedule item
numbers (http://www.mbsonline.gov.au/) were used to
estimate the costs of surgeon and anaesthetists time and
in total were $5610 for TLH and $5460 for TAH. Nursing
costs of $46.22/h were used to reﬂect a Grade 6 Nurse
and it was assumed that 2.5 nurses are required to
support either a TLH or TAH. The duration of each
surgery was used to estimate nursing costs per case. One
hour of nursing time was added for preparation and
clean up. Medicare Beneﬁts Schedule item numbers
were also used to value the subsequent use of consulta-
tions with GPs ($120.3), consultations with psychiatrist,
psychologist or other mental health counsellors ($249.3),
visits to the emergency department ($200.95), short con-
sultations with nurse practitioner, home health nurse,
physical/occupational or respiratory therapist ($22.7)
and visits to a hospital out-patient department ($200.95).
The cost of a night in a hospital bed was valued at $1133;
this was derived by adjusting estimates published by
Australian Institute of Health & Welfare to 2011 prices.14
The most useful results from the modelling that com-
pared TLH with TAH are shown in table 2.
On average, the higher surgery costs of TLH over
TAH are compensated by cost savings in health services
that accrue in the 6 months after surgery. In particular
3.55 hospital bed days are saved for each patient who
has TLH, and there are extrahealth beneﬁts of 0.04
QALYs that accrue during the 1825 days of model dur-
ation. The uncertainty in the data is shown by ﬁgure 1,
which illustrates the joint distribution of change to costs
and health beneﬁts from a decision to adopt TLH over
TAH. The distributions of the total cost and QALY out-
comes are shown in online supplementary appendix 1.
The adoption of TLH over TAH will always save costs
and there is 86.8% probability that health beneﬁts will
be increased, which means a high chance of health ser-
vices enjoying a ‘win win’. The distribution of the net
monetary beneﬁt of a decision to adopt TLH over TAH
is shown in ﬁgure 2 and there is a 99.5% probability that
the net monetary beneﬁt from adoption TLH over TAH
will be greater than zero. The area to the left of the
dashed line at zero in ﬁgure 2 is 0.05% of the area
under this curve.
Model results did change when the patients with
lymph-node dissection were excluded: the difference in
surgery costs fell from $510 to $482, the savings in
lengths of stay fell from 3.55 to 3.38, total cost savings
fell from $3746 to $3734 and QALY gains were reduced
from 0.04 to 0.03. Under this scenario, the adoption of
TLH over TAH will again always save costs and there is
79.8% probability that health beneﬁts will be increased.
There is a 98.3% probability that the net monetary
beneﬁt from adoption TLH over TAH will be greater
than zero, providing strong evidence that adoption is a
good decision.
DISCUSSION
Based on the data, we have used the adoption of TLH
which is almost certainly a good decision for health ser-
vices policy makers. There is 100% probability that it will
be cost saving to health services, a 86.8% probability that
it will increase health beneﬁts, although the QoL bene-
ﬁts are modest for the average individual, and a 99.5%
chance that it returns net monetary beneﬁts that are
greater than zero. Our ﬁndings are in line with previous
reports from the literature. A Dutch study by Bijen et al17
also reported higher costs for TLH offset by a shorter
hospital stay. Within the 3-month follow-up period, the
QoL outcomes were similar between the two treatments.
Further analysis of trial data found TLH cost-effective
for patients >70 years of age, but not for very obese
patients with body mass index > 35.18 In another clinical
trial of hysterectomy for benign diagnoses, Garry et al19
not only reported higher complication rates for LH but
also conﬁrmed a shorter hospital stay and faster post-
operative recovery compared to TAH. Sculpher et al20
found higher costs of laparoscopic hysterectomy com-
pared to abdominal hysterectomy (£186) with similar
QALYs resulting in incremental costs of £26 571 for each
Table 1 EQ-5D scores from all trial participants
TAH (mean (SD)) TLH (Mean (SD))
1 week 0.63 (0.24) 0.71 (0.23)
4 weeks 0.79 (0.22) 0.84 (0.19)
3 months 0.82 (0.25) 0.86 (0.22)
6 months 0.82 (0.27) 0.86 (0.23)
TAH, total abdominal hysterectomy; TLH, total laparoscopic
hysterectomy.
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QALY gained. There was only a 56% probability that lap-
aroscopic hysterectomy is cost-effective. It should be
noted that health outcomes were not measured before
or immediately after the procedure, but merely 6 weeks
later which may underestimate true health beneﬁts and
hence understate the overall cost-effectiveness. The dif-
ferences in hospital length of stay between the treat-
ments were also small in this trial. A large difference of
3.55 days found in our data (table 1) was the main
driver of cost savings.
Studies from the USA,21 Australia,22 France23 and the
UK24 found costs of TAH and TLH to be similar or not
signiﬁcantly different and consistently reported a signiﬁ-
cantly shorter hospital stay for TLH. A recent cost com-
parison of different treatment approaches for
endometrial cancer found TLH to be the least expensive
alternative with costs ranging from US$6581–US$10 128
compared to US$7009–US$12 847 for TAH, depending
on the range of costs included in the analysis.25 In con-
trast, a study by Lumsden et al26 with randomised
Scottish patients reported higher overall costs for LH
due to higher operation costs which were not compen-
sated by the decreased length of stay or similar QoL out-
comes. They concluded that LH is unlikely to be
cost-effective in the National Health Services (NHS)
context. Similarly, a large cross-sectional analysis by
Campbell et al27 associated TLH with higher hospital
costs. This was conﬁrmed by Lenihan et al,28 but they
also noted decreased indirect costs to employers due to
a faster recovery and fewer hours at work lost.
Although cost estimates may vary due to different
patient populations, perspectives, surgical and measure-
ment techniques, the majority of recently published lit-
erature favours TLH over TAH economically.29 We
believe that our ﬁndings derived from the large multi-
centre LACE trial represent an accurate estimate of out-
comes. The use of TLH is recommended although
decisions on the technique employed should be based
on individual patient circumstances, including age and
comorbidities. Future studies could look at long-term
effects from a societal perspective. The data from Walker
et al12 were used to show mortality risks for the two com-
peting treatments. The reasons for this are their data
were complete for a 5-year period and were audited with
all follow-up-consistent and survival status obtained for
each patient at the time of database lock, this is not the
case for the LACE mortality outcomes; their publication
has be reviewed by referees, statistical methods have
been independently agreed upon and as such the sur-
vival curves for both groups reﬂect the scientiﬁc design
for a non-inferiority equivalence design, this is yet to be
achieved for the LACE trial.
Our data show that TLH is a safe and cost-effective
treatment approach for early endometrial cancer and is
Figure 1 Joint distribution of change to costs and health
benefits from a decision to adopt total laparoscopic
hysterectomy (TLH) over total abdominal hysterectomy (TAH).
Figure 2 Distribution of the net monetary benefit of a
decision to adopt adopt total laparoscopic hysterectomy (TLH)
over total abdominal hysterectomy (TAH).
Table 2 Results from cost-effectiveness model
TAH (mean (SD)) TLH (mean (SD)) Difference per patient Difference for 1000 patients
Surgery costs ($) 6755 (4.76) 7265 (3.93) 510 509575.37
Bed days used* 7.31 (0.52) 3.76 (0.24) −3.55 −3548.18
Total costs ($)† 15870 (637) 12124 (311) −3746 −3746221.69
QALYs‡ 3.42 (0.046) 3.46 (0.039) 0.04 39.13
*For the recovery from surgery and for subsequent admissions within 6 months.
†This includes all health services used from surgery to 6 months after.
‡For the 1825 days described by the model.
TAH, total abdominal hysterectomy; TLH, total laparoscopic hysterectomy.
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likely to improve patients’ health outcomes whilst saving
healthcare resources. The main drivers of the cost
savings are reduced length of stay and reduced compli-
cations. Data from LACE11 however show complications
were 14.3% for TAH and 8.2% in TLH, operating time
was lower (132 vs 107 min) and length of stay in hospital
was reduced from 5 to 2 days. Another recent study from
the USA7 showed TLH had fewer moderate to severe
postoperative adverse events (14% vs 21%), similar rates
of intraoperative complications, but the length of hos-
pital say was reduced by 2 days. To date, hysterectomy
remains the most common major gynaecological surgical
procedure, but the uptake of TLH amongst gynaeco-
logical surgeons has been slow. Further research might
examine how a minimally invasive surgical approach can
be established in real, day-to-day clinical practice to the
beneﬁt of women and their communities.
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